在实验性疟疾模型中,伊塔科纳酸具有有限的保护作用
Fran Prenen1, Emilie Pollenus1, Hanne Meers1,2
1Laboratory of Immunoparasitology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
European journal of immunology
|May 10, 2025
概括
它的代谢物伊塔科纳酸并不能使疟疾恶化. 研究表明,伊塔科纳酸对疟疾提供有限的保护,与最近的发现相反,强调其治疗潜力.
科学领域:
- 免疫代谢过程中的免疫代谢.
- 疟疾的发病因子疟疾的发病因子
- 代谢物治疗学 代谢物治疗学
背景情况:
- 严重的疟疾涉及代谢失调和炎症,需要针对两者的治疗.
- 由ACOD1产生的伊塔科纳酸抑制炎症和糖解,在炎症性疾病中显示出有前途.
- 疟疾中伊塔科纳酸盐的高含量表明有作用,但其确切的功能仍然不清楚.
研究的目的:
- 为了研究伊塔科纳酸在疟疾病原发生中的作用.
- 评估itaconate在疟疾中的治疗潜力.
- 为了澄清伊塔科纳酸对疟疾易感性或保护的贡献.
主要方法:
- 使用了Plasmodium berghei NK65 (严重) 和Plasmodium chabaudi AS (轻微) 的小鼠模型.
- 采用13C-标志物代谢学来追踪伊塔可纳酸盐的生产和分销.
- 分析了ACOD1淘汰赛小鼠和4-octyl itaconate治疗对疾病的影响.
主要成果:
- 在感染期间,在器官中检测到增加的伊塔科纳酸盐水平,炎症单细胞被确定为生产者.
- 在重型疟疾模型 (PbNK65) 中,ACOD1淘汰赛小鼠没有显著变化.
- 在轻度疟疾模型 (PcAS) 中,ACOD1缺乏会加剧疾病,增加体重减轻,临床分数和寄生病.
结论:
- 伊塔科纳酸盐不会导致疟疾易感.
- 伊塔科纳酸在疟疾中提供一定程度的保护,特别是在PcAS模型中.
- 这些发现挑战了最近的文献,表明itaconate在疟疾中起着保护作用,而不是有害作用.
更多相关视频
08:46Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites
Published on: May 18, 2016
17.1K
08:20In Vitro Assay of Plasmodium-Infected Red Blood Cell Killing by Cytotoxic Lymphocytes
Published on: August 17, 2022
2.0K
相关概念视频
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...